Abstract | INTRODUCTION: AIM: To review the clinical evidence (phase II and III studies) of the effectiveness and safety of febuxostat for treatment of hyperuricemia and gout. EVIDENCE REVIEW:
Febuxostat, at doses ranging from 40 to 240 mg/day, is efficacious in reducing serum urate in patients with hyperuricemia and gout, comparing favorably with fixed doses of allopurinol in that respect. Early safety signals with respect to liver test abnormalities and cardiovascular outcomes have not been confirmed in recent large prospective trials but need to be further monitored. CLINICAL POTENTIAL: Given its low cost and extensive clinical experience, allopurinol will likely remain the first-line drug for management of hyperuricemia and gout. Febuxostat may provide an important option in patients unable to use allopurinol, those with very high serum urate levels, or in the presence of refractory tophi.
|
Authors | Angelo L Gaffo, Kenneth G Saag |
Journal | Core evidence
(Core Evid)
Vol. 4
Pg. 25-36
(Jun 15 2010)
ISSN: 1555-175X [Electronic] New Zealand |
PMID | 20694062
(Publication Type: Journal Article)
|